These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37772620)

  • 1. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
    Sportoletti P; Laurenti L; Chiarenza A; Gaidano G; Albi E; Mauro FR; Trentin L; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Coscia M; Gozzetti A; Reda G; Caira M; Finsinger P; Gualberti G; Iannella E; Malgieri S; Molica S
    Hematol Oncol; 2024 Jan; 42(1):e3216. PubMed ID: 37772620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.
    Boqué C; Abad MR; Agustín MJ; García-Goñi M; Moreno C; Gabás-Rivera C; Granados E; Castro-Gómez A; Pardo C; Lizán L
    J Geriatr Oncol; 2020 Jan; 11(1):24-30. PubMed ID: 30954406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment.
    Ravelo A; Myers K; Brumble R; Bussberg C; Koffman B; Manzoor BS; Biondo JML; Mansfield C
    Future Oncol; 2024; 20(28):2059-2070. PubMed ID: 38861284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment.
    Laurenti L; Gaidano G; Mauro FR; Molica S; Pasqualetti P; Scarfò L; Ghia P
    Hemasphere; 2022 Sep; 6(9):e771. PubMed ID: 36081648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the experience, treatment preferences and goals of people living with chronic lymphocytic leukemia (CLL) in Australia.
    Fifer S; Godsell J; Opat S; Hamad N; Lasica M; Forsyth C; Morand L; Smeaton E; Winton S; Puig A; McGeachie M
    BMC Cancer; 2024 Jul; 24(1):831. PubMed ID: 38992616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.
    Holtzer-Goor KM; Schaafsma MR; Joosten P; Posthuma EF; Wittebol S; Huijgens PC; Mattijssen EJ; Vreugdenhil G; Visser H; Peters WG; Erjavec Z; Wijermans PW; Daenen SM; van der Hem KG; van Oers MH; Uyl-de Groot CA
    Qual Life Res; 2015 Dec; 24(12):2895-906. PubMed ID: 26205768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
    Mühlbacher AC; Nübling M
    Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients' priorities in selecting chronic lymphocytic leukemia treatments.
    Mansfield C; Masaquel A; Sutphin J; Weiss E; Gutierrez M; Wilson J; Boeri M; Li J; Reyes C
    Blood Adv; 2017 Nov; 1(24):2176-2185. PubMed ID: 29296865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis.
    Landfeldt E; Eriksson J; Ireland S; Musingarimi P; Jackson C; Tweats E; Gaudig M
    Leuk Res; 2016 Jan; 40():17-23. PubMed ID: 26654707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ-C30 and QLQ-CLL17 questionnaire.
    Youron P; Singh C; Jindal N; Malhotra P; Khadwal A; Jain A; Prakash G; Varma N; Varma S; Lad DP
    Eur J Haematol; 2020 Dec; 105(6):755-762. PubMed ID: 32748412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study.
    Hong Y; Chen X; Hong Y; Xiao X; Wang Y; You X; Mi J; Zhou T; Zheng P; Huang Z
    BMC Health Serv Res; 2023 Dec; 23(1):1355. PubMed ID: 38049834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
    Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
    [No Abstract]   [Full Text] [Related]  

  • 20. Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment.
    Borsoi L; Costa F; Milano C; Segantin G; Ghia P; Armeni P
    Leuk Lymphoma; 2024 Nov; 65(11):1565-1575. PubMed ID: 38980060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.